Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

First Posted Date
2008-03-26
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
525
Registration Number
NCT00644228
Locations
🇺🇸

Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States

🇺🇸

Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States

🇺🇸

OSF Saint Anthony's Health Center, Alton, Illinois, United States

and more 496 locations

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-03-12
Last Posted Date
2023-02-09
Lead Sponsor
University of Pennsylvania
Target Recruit Count
5
Registration Number
NCT00633945
Locations
🇺🇸

Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

First Posted Date
2008-03-12
Last Posted Date
2017-01-31
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
39
Registration Number
NCT00633594
Locations
🇺🇸

Providence Medical Group, Terre Haute, Indiana, United States

🇺🇸

RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States

🇺🇸

Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States

and more 4 locations

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-03-10
Last Posted Date
2020-02-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
33
Registration Number
NCT00632359
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-02-25
Last Posted Date
2019-11-20
Lead Sponsor
Celgene
Target Recruit Count
330
Registration Number
NCT00622336
Locations
🇷🇺

Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod, Russian Federation

🇺🇦

Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkov, Ukraine

🇺🇦

Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine

and more 4 locations

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Phase 1
Completed
Conditions
First Posted Date
2008-02-22
Last Posted Date
2011-05-10
Lead Sponsor
Nantes University Hospital
Target Recruit Count
27
Registration Number
NCT00621400
Locations
🇫🇷

Hôpital Saint-Louis, Paris, France

🇫🇷

CHRU d'Amiens, Amiens, France

🇫🇷

CHRU de Lille, Lille, France

and more 9 locations

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

First Posted Date
2008-02-21
Last Posted Date
2017-05-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
18
Registration Number
NCT00619684
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

First Posted Date
2008-02-18
Last Posted Date
2014-01-17
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
57
Registration Number
NCT00617591
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

First Posted Date
2008-02-07
Last Posted Date
2015-09-17
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
29
Registration Number
NCT00609869
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

🇺🇸

Center for Cancer Care & Research/Watson, Lakeland, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath